secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001396814-24-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30
--------------------------------------------------------------------------------

- Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.
- Full-year 2023 total revenue $675.0M (+1% YoY), GAAP net income $42.0M ($0.91 basic EPS), adj EBITDA $214.5M.
- CFO Charles Reinhart to depart effective Sept 30, 2024; transition services through June 2025; search for successor underway.
- 2024 guidance: total revenue $680M-$705M; non-GAAP gross margin 74%-76%; R&D $70M-$80M; SG&A $245M-$265M.
- FDA approved new 200L EXPAREL manufacturing suite in Feb 2024; expects commercial product later this year to benefit gross margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/pcrx-20240226.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer